Abstract：
Invasive lobular cancer (ILC) is the most common of the breast cancer special types, accounting for up to 15% of all breast malignancies. The distinctive biological features of ILC include the loss of the cell adhesion molecule E-cadherin, which drives the tumor\'s peculiar discohesive growth pattern, with cells arranged in single file and dispersed throughout the stroma. Typically, such tumors originate in the lobules, are more commonly bilateral compared to invasive ductal cancer (IDC) and require a more accurate diagnostic examination through imaging. They are luminal in molecular subtype, and exhibit estrogen and progesterone receptor positivity and HER2 negativity, thus presenting a more unpredictable response to neoadjuvant therapies. There has been a significant increase in research focused on this distinctive breast cancer subtype, including studies on its pathology, its clinical and surgical management, and the high-resolution definition of its genomic profile, as well as the development of new therapeutic perspectives. This review will summarize the heterogeneous pattern of this unique disease, focusing on challenges in its comprehensive clinical management and on future insights and research objectives.
摘要：
浸润性小叶癌(ILC)是乳腺癌中最常见的特殊类型,占所有乳腺恶性肿瘤的15%。ILC的独特生物学特征包括细胞粘附分子E-cadherin的丢失，这驱动了肿瘤特有的盘状生长模式，细胞排列在单个文件中，分散在整个基质中。通常,这种肿瘤起源于小叶，与浸润性导管癌（IDC）相比，更常见的是双侧的，并且需要通过成像进行更准确的诊断检查。它们是分子亚型的管腔，并表现出雌激素和孕激素受体阳性和HER2阴性，因此，对新辅助疗法的反应更加不可预测。针对这种独特的乳腺癌亚型的研究显着增加，包括对其病理学的研究，其临床和手术管理，以及其基因组图谱的高分辨率定义，以及新的治疗观点的发展。这篇综述将总结这种独特的疾病的异质性模式，重点关注其全面临床管理中的挑战以及未来的见解和研究目标。
